$PLX
Protalix BioTherapeutics, Inc. Stock $plx

$plx Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-K Financial Statement

#000114420414015468 Filed on March 13, 2014

Income Statement

Concept	2014 Q1	2013	2012 Q4
Revenue	$6.696M	$0.00	$50.00K
YoY Change	87.67%	-100.0%	-92.75%
Cost Of Revenue	$4.073M	$0.00	$1.180M
YoY Change	319.46%	-100.0%	195.0%
Gross Profit	$3.310M	$0.00	-$1.130M
YoY Change	10.44%	-100.0%	-489.66%
Gross Profit Margin	49.43%		-2260.0%
Selling, General & Admin	$3.711M	$8.051M	$2.410M
YoY Change	76.46%	-17.54%	-71.28%
% of Gross Profit	112.11%
Research & Development	$8.152M	$29.23M	$970.0K
YoY Change	5.13%	-20.29%	27.63%
% of Gross Profit	246.28%
Depreciation & Amortization	$828.0K	$3.539M	$920.0K
YoY Change	-10.97%	-4.14%	-1.08%
% of Gross Profit	25.02%
Operating Expenses	$11.86M	$37.28M	$9.040M
YoY Change	20.35%	-19.71%	-1.2%
Operating Profit	-$6.468M	-$34.06M	-$10.17M
YoY Change	46.04%	179.85%	14.79%
Interest Expense	-$880.0K	$1.015M	$290.0K
YoY Change	-900.0%	84.55%	-583.33%
% of Operating Profit
Other Income/Expense, Net	-$877.0K	-$674.0K
YoY Change	-912.04%	-221.66%
Pretax Income	-$7.350M	-$34.74M	-$9.880M
YoY Change	70.14%	198.97%	10.89%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$7.345M	-$27.79M	-$9.880M
YoY Change	69.98%	139.2%	10.89%
Net Earnings / Revenue	-109.69%		-19760.0%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.79	-$3.00	-$1.15
COMMON SHARES
Basic Shares Outstanding	93.58M shares		93.47M
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q1	2013	2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$77.70M	$86.80M	$52.00M
YoY Change	85.44%	59.56%	92.59%
Cash & Equivalents	$77.69M	$86.40M	$52.04M
Short-Term Investments		$400.0K
Other Short-Term Assets	$2.600M	$1.100M	$3.700M
YoY Change	-27.78%	-15.38%	-2.63%
Inventory	$6.527M	$8.000M	$4.039M
Prepaid Expenses			$251.0K
Receivables	$1.735M	$2.100M	$1.410M
Other Receivables	$2.609M	$0.00	$3.686M
Total Short-Term Assets	$88.56M	$97.90M	$61.17M
YoY Change	67.43%	59.97%	88.27%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.10M	$13.70M	$16.31M
YoY Change	-16.6%	-15.95%	-10.73%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.800M	$1.700M	$1.200M
YoY Change	38.46%	41.67%	20.0%
Total Long-Term Assets	$14.86M	$15.40M	$17.56M
YoY Change	-12.86%	-12.0%	-9.1%
TOTAL ASSETS
Total Short-Term Assets	$88.56M	$97.90M	$61.17M
Total Long-Term Assets	$14.86M	$15.40M	$17.56M
Total Assets	$103.4M	$113.3M	$78.73M
YoY Change	47.86%	43.96%	51.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.600M	$11.20M	$5.300M
YoY Change	21.05%	16.67%	6.0%
Accrued Expenses		$4.200M	$2.032M
YoY Change		10.53%	-12.68%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$26.78M	$26.70M	$25.76M
YoY Change	9.72%	3.49%	37.78%
LONG-TERM LIABILITIES
Long-Term Debt		$67.00M	$5.425M
YoY Change			-17.38%
Other Long-Term Liabilities	$43.10M	$46.50M	$56.30M
YoY Change	-16.8%	-17.41%	757.45%
Total Long-Term Liabilities	$110.2M	$113.5M	$56.33M
YoY Change	112.7%	101.6%	-4.83%
TOTAL LIABILITIES
Total Short-Term Liabilities	$26.78M	$26.70M	$25.76M
Total Long-Term Liabilities	$110.2M	$113.5M	$56.33M
Total Liabilities	$137.0M	$140.3M	$82.08M
YoY Change	79.72%	70.89%	5.4%
SHAREHOLDERS EQUITY
Retained Earnings			-$183.6M
YoY Change			6.76%
Common Stock			$180.2M
YoY Change			23.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$33.58M	-$26.90M	-$3.357M
YoY Change
Total Liabilities & Shareholders Equity	$103.4M	$113.3M	$78.73M
YoY Change	47.86%	43.96%	51.97%

Cashflow Statement

Concept	2014 Q1	2013	2012 Q4
OPERATING ACTIVITIES
Net Income	-$7.345M	-$27.79M	-$9.880M
YoY Change	69.98%	139.2%	10.89%
Depreciation, Depletion And Amortization	$828.0K	$3.539M	$920.0K
YoY Change	-10.97%	-4.14%	-1.08%
Cash From Operating Activities	-$8.340M	-$30.65M	$1.830M
YoY Change	-13.0%	-4927.24%	-127.69%
INVESTING ACTIVITIES
Capital Expenditures	$263.0K	$1.890M	$250.0K
YoY Change	-59.03%	-8.61%	-64.79%
Acquisitions
YoY Change
Other Investing Activities	$50.00K	$170.0K	-$130.0K
YoY Change	6.38%	23.19%	225.0%
Cash From Investing Activities	-$370.0K	-$2.102M	-$380.0K
YoY Change	-46.3%	-8.05%	-49.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	30.00K	66.89M	140.0K
YoY Change		151.86%	600.0%
NET CHANGE
Cash From Operating Activities	-8.340M	-$30.65M	1.830M
Cash From Investing Activities	-370.0K	-$2.102M	-380.0K
Cash From Financing Activities	30.00K	66.89M	140.0K
Net Change In Cash	-8.680M	-$32.76M	1.590M
YoY Change	-15.52%	-231.51%	-121.66%
FREE CASH FLOW
Cash From Operating Activities	-$8.340M	-$30.65M	$1.830M
Capital Expenditures	$263.0K	$1.890M	$250.0K
Free Cash Flow	-$8.603M	-$32.54M	$1.580M
YoY Change	-15.89%	2170.97%	-121.58%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013	dei	Amendment Flag AmendmentFlag	false
CY2013	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2013	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013	dei	Document Period End Date DocumentPeriodEndDate	2013-12-31
CY2013	dei	Document Type DocumentType	10-K
CY2013	dei	Entity Central Index Key EntityCentralIndexKey	0001006281
CY2014Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	93580464	shares
CY2013	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2013Q2	dei	Entity Public Float EntityPublicFloat	286000000	USD
CY2013	dei	Entity Registrant Name EntityRegistrantName	PROTALIX BIOTHERAPEUTICS, INC.
CY2013	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2013	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2013	dei	Trading Symbol TradingSymbol	PLX
CY2013	plx	Amortization Of Debt Issuance Costs AmortizationOfDebtIssuanceCosts	127000	USD
CY2013	plx	Cashless Exercise Of Stock Options CashlessExerciseOfStockOptions		USD
CY2012	plx	Cashless Exercise Of Stock Options CashlessExerciseOfStockOptions		USD
CY2011	plx	Cashless Exercise Of Stock Options CashlessExerciseOfStockOptions	31000	USD
CY2013	plx	Commitment Amount CommitmentAmount	1100000	USD
CY2013Q3	plx	Debt Instrument Convertible Base Value For Conversion Rate DebtInstrumentConvertibleBaseValueForConversionRate	1000	USD
CY2013Q3	plx	Debt Instrument Convertible Conversion Share Number DebtInstrumentConvertibleConversionShareNumber	173.6593	shares
CY2013	plx	Depreciation Amortization And Asset Impairment DepreciationAmortizationAndAssetImpairment	3539000	USD
CY2012	plx	Depreciation Amortization And Asset Impairment DepreciationAmortizationAndAssetImpairment	3692000	USD
CY2011	plx	Depreciation Amortization And Asset Impairment DepreciationAmortizationAndAssetImpairment	3631000	USD
CY2013	plx	Employee Severance Obligation Payment EmployeeSeveranceObligationPayment	194000	USD
CY2012	plx	Employee Severance Obligation Payment EmployeeSeveranceObligationPayment	177000	USD
CY2011	plx	Employee Severance Obligation Payment EmployeeSeveranceObligationPayment	181000	USD
CY2013	plx	Expected Definted Benefit Contribution During Period ExpectedDefintedBenefitContributionDuringPeriod	847000	USD
CY2013	plx	Expected Severance Liabilities Payments For Future Period ExpectedSeveranceLiabilitiesPaymentsForFuturePeriod	1100000	USD
CY2013	plx	Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement	58000	USD
CY2012	plx	Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement	36000	USD
CY2011	plx	Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement	14000	USD
CY2013	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	8497000	USD
CY2012	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	7976000	USD
CY2011	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	6775000	USD
CY2013	plx	Increase In Liabilities For Property Plant And Equipment IncreaseInLiabilitiesForPropertyPlantAndEquipment	186000	USD
CY2012	plx	Increase In Liabilities For Property Plant And Equipment IncreaseInLiabilitiesForPropertyPlantAndEquipment	1136000	USD
CY2011	plx	Increase In Liabilities For Property Plant And Equipment IncreaseInLiabilitiesForPropertyPlantAndEquipment	1473000	USD
CY2013	plx	Number Of Subsidiaries NumberOfSubsidiaries	2	pure
CY2013	plx	Other Gains Losses OtherGainsLosses	1034000	USD
CY2012	plx	Other Gains Losses OtherGainsLosses	-446000	USD
CY2011	plx	Other Gains Losses OtherGainsLosses	-5418000	USD
CY2013	plx	Proceeds From Issuance Of Common Stock Net Of Expenses ProceedsFromIssuanceOfCommonStockNetOfExpenses		USD
CY2012	plx	Proceeds From Issuance Of Common Stock Net Of Expenses ProceedsFromIssuanceOfCommonStockNetOfExpenses	25328000	USD
CY2011	plx	Proceeds From Issuance Of Common Stock Net Of Expenses ProceedsFromIssuanceOfCommonStockNetOfExpenses	20650000	USD
CY2013	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	24816000	USD
CY2012	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	28689000	USD
CY2011	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	31043000	USD
CY2013	plx	Revenue Recognized Over Designated Period RevenueRecognizedOverDesignatedPeriod	4600000	USD
CY2013	plx	Revenue Recognized Period RevenueRecognizedPeriod	P14Y
CY2012Q4	plx	Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue	8600000	USD
CY2013	plx	Share Based Compensation Restricted Stock Awards Net Of Forfeitures ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures	3076000	USD
CY2012	plx	Share Based Compensation Restricted Stock Awards Net Of Forfeitures ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures	3139000	USD
CY2013	plx	Supplemental Offering And Stock Issuance Costs SupplementalOfferingAndStockIssuanceCosts		USD
CY2012	plx	Supplemental Offering And Stock Issuance Costs SupplementalOfferingAndStockIssuanceCosts		USD
CY2011	plx	Supplemental Offering And Stock Issuance Costs SupplementalOfferingAndStockIssuanceCosts	60000	USD
CY2013Q4	plx	Withholding Tax Rate On Foreign Income WithholdingTaxRateOnForeignIncome	0.15	pure
CY2013Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	12073000	USD
CY2012Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	11051000	USD
CY2013Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	5254000	USD
CY2012Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	5267000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2091000	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1410000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1785000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2032000	USD
CY2013Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	419000	USD
CY2012Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1560000	USD
CY2013Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	1572000	USD
CY2012Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	1453000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	18319000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14786000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	184346000	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	180145000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1013000	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4612000	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	886000	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1780000	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1410000	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4089000	USD
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7751000	USD
CY2011	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	886000	USD
CY2013	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	127000	USD
CY2012	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		USD
CY2011	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		USD
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10675304	shares
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7280469	shares
CY2011	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7469088	shares
CY2013	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2012	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2011	us-gaap	Asset Impairment Charges AssetImpairmentCharges	10000	USD
CY2013Q4	us-gaap	Assets Assets	113333000	USD
CY2012Q4	us-gaap	Assets Assets	78727000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	97903000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	61170000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	86398000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52035000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27001000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35900000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	34363000	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	25034000	USD
CY2011	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-8899000	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	93551098	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	93489809	shares
CY2012Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5175000	shares
CY2011Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4000000	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	93551098	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	93489809	shares
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	93000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	93000	USD
CY2013	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> </td> <td><strong>Concentration of credit risks and trade receivable</strong></td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal">  </p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> Financial instruments that potentially subject the Company to concentration of credit risk consist principally of bank deposits. The Company deposits these instruments with highly rated financial institutions, mainly in Israeli banks, and, as a matter of policy, limits the amounts of credit exposure to any one financial institution. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these instruments.</p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal">  </p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> The Company's trade receivable represents amounts to be received from Pfizer and the Company's customers in Israel. The Company does not require Pfizer or any of its Israeli customers to post collateral with respect to receivables. The Company performs periodic credit evaluations of Pfizer's financial condition and believes there is no significant risk with respect to Pfizer's payment of the receivables. As all Israeli customers are government entities, the Company believes there is no significant risk with respect to its receivables from such entities.</p> <!--EndFragment--></div> </div>
CY2013Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	72000000	USD
CY2013Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	67048000	USD
CY2012Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent		USD
CY2013	us-gaap	Cost Of Revenue CostOfRevenue	5428000	USD
CY2012	us-gaap	Cost Of Revenue CostOfRevenue	8144000	USD
CY2011	us-gaap	Cost Of Revenue CostOfRevenue	1525000	USD
CY2013Q3	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	5.76
CY2013Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	69000000	USD
CY2013Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.045	pure
CY2013Q3	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2018-09-15
CY2013Q4	us-gaap	Deferred Costs DeferredCosts	141000	USD
CY2012Q4	us-gaap	Deferred Costs DeferredCosts		USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	9369000	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	9437000	USD
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	41796000	USD
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	48888000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	9867000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	10449000	USD
CY2013Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5257000	USD
CY2012Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	6003000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		USD
CY2012Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		USD
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	23167000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15176000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	-491000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	-647000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	417000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	363000	USD
CY2013	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	264000	USD
CY2012	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	171000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Severance Payments DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments	209000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Severance Payments DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments	192000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	38426000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	31536000	USD
CY2013	us-gaap	Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Loss Net Gain Loss Before Tax DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax	58000	USD
CY2012	us-gaap	Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Loss Net Gain Loss Before Tax DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax	36000	USD
CY2011	us-gaap	Defined Benefit Plan Amounts Recognized In Other Comprehensive Income Loss Net Gain Loss Before Tax DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax	14000	USD
CY2013Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1578000	USD
CY2012Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1247000	USD
CY2013	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	801000	USD
CY2012	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	670000	USD
CY2011	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	641000	USD
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.3
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
CY2011	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.43
CY2013	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	226000	USD
CY2012	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	127000	USD
CY2011	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-388000	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1557000	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1748000	USD
CY2013Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2700000	USD
CY2013	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P9M18D
CY2011	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-350000	USD
CY2013	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		USD
CY2012	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment		USD
CY2011	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-8000	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8385000	USD
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9763000	USD
CY2011	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6931000	USD
CY2013	us-gaap	Gross Profit GrossProfit	6085000	USD
CY2012	us-gaap	Gross Profit GrossProfit	26280000	USD
CY2011	us-gaap	Gross Profit GrossProfit	1443000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1322000	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2977000	USD
CY2011	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6147000	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1904000	USD
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-243000	USD
CY2011	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3891000	USD
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-7160000	USD
CY2012	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1281000	USD
CY2011	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3005000	USD
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3918000	USD
CY2012	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3760000	USD
CY2011	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-910000	USD
CY2013	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	42000	USD
CY2012	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	80000	USD
CY2011	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash		USD
CY2013	us-gaap	Interest Expense InterestExpense	1015000	USD
CY2013	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	888000	USD
CY2013Q4	us-gaap	Interest Payable Current InterestPayableCurrent	888000	USD
CY2012Q4	us-gaap	Interest Payable Current InterestPayableCurrent		USD
CY2013Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5523000	USD
CY2012Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1729000	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	7957000	USD
CY2012Q4	us-gaap	Inventory Net InventoryNet	4039000	USD
CY2013Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2342000	USD
CY2012Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2118000	USD
CY2013Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	92000	USD
CY2012Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	192000	USD
CY2013	us-gaap	Inventory Write Down InventoryWriteDown	1600000	USD
CY2012	us-gaap	Inventory Write Down InventoryWriteDown	684000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	140279000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	82084000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	113333000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	78727000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	26696000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25755000	USD
CY2013Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	113583000	USD
CY2012Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	56329000	USD
CY2013Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2371000	USD
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5425000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	66892000	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	26558000	USD
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	20927000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-2102000	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-2286000	USD
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-5868000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-30653000	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	635000	USD
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-23570000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-27790000	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-11618000	USD
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-36529000	USD
CY2013	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-674000	USD
CY2012	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	554000	USD
CY2011	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-27116000	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-12172000	USD
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	-36531000	USD
CY2013Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	112700000	USD
CY2013Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1457000	USD
CY2012Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	3686000	USD
CY2013	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	170000	USD
CY2012	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	138000	USD
CY2011	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	165000	USD
CY2012Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1800000	USD
CY2011Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1400000	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1890000	USD
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2068000	USD
CY2011	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5705000	USD
CY2013Q4	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	2368000	USD
CY2012Q4	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	2016000	USD
CY2013	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	200000	USD
CY2012	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	276000	USD
CY2011	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	155000	USD
CY2013	us-gaap	Postemployment Benefits Period Expense PostemploymentBenefitsPeriodExpense	1000000	USD
CY2012	us-gaap	Postemployment Benefits Period Expense PostemploymentBenefitsPeriodExpense	1000000	USD
CY2011	us-gaap	Postemployment Benefits Period Expense PostemploymentBenefitsPeriodExpense	816000	USD
CY2013Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	286000	USD
CY2012Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	251000	USD
CY2009Q4	us-gaap	Proceeds From Collaborators ProceedsFromCollaborators	60000000	USD
CY2013	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	66780000	USD
CY2012	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		USD
CY2011	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		USD
CY2012Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25400000	USD
CY2011Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20600000	USD
CY2013Q3	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	9000000	USD
CY2013Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	66800000	USD
CY2013	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		USD
CY2012	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		USD
CY2011	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2000	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	112000	USD
CY2012	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1230000	USD
CY2011	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	277000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	32030000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	31096000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13711000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16310000	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33313000	USD
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36665000	USD
CY2011	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	37818000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-211385000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-183595000	USD
CY2013	us-gaap	Revenues Revenues	10479000	USD
CY2012	us-gaap	Revenues Revenues	34870000	USD
CY2011	us-gaap	Revenues Revenues	8386000	USD
CY2012Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	5.25
CY2011Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	5.5
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	4089000	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	7751000	USD
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	886000	USD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	17834	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	3208	shares
CY2006Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	9741655	shares
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	11341655	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1500000	shares
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-26946000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-3357000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	-26077000	USD
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	-11323000	USD
CY2012	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	25388000	USD
CY2011	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	20590000	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	112000	USD
CY2012	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1199000	USD
CY2011	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	299000	USD
CY2013	us-gaap	Use Of Estimates UseOfEstimates	<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --><div> <div><!--StartFragment--> <table style="MARGIN-BOTTOM: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-TOP: 0pt; font-size-adjust: none; font-stretch: normal" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td><strong>Use of estimates in the preparation of financial statements</strong></td> </tr> </table> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal">  </p> <p style="FONT: 10pt Times New Roman, Times, Serif; MARGIN: 0pt 0px 0pt 0.75in; font-size-adjust: none; font-stretch: normal"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.</p> <!--EndFragment--></div> </div>
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	92368138	shares
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	90845901	shares
CY2011	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	84645364	shares

Files In Submission

Name	View Source	Status
0001144204-14-015468-index-headers.html	Edgar Link	pending
0001144204-14-015468-index.html	Edgar Link	pending
0001144204-14-015468.txt	Edgar Link	pending
0001144204-14-015468-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
plx-20131231.xml	Edgar Link	completed
plx-20131231.xsd	Edgar Link	pending
plx-20131231_cal.xml	Edgar Link	unprocessable
plx-20131231_def.xml	Edgar Link	unprocessable
plx-20131231_lab.xml	Edgar Link	unprocessable
plx-20131231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tpg17a.jpg	Edgar Link	pending
tpg17b.jpg	Edgar Link	pending
tpg17c.jpg	Edgar Link	pending
tpg19a.jpg	Edgar Link	pending
tpg19b.jpg	Edgar Link	pending
tpg57.jpg	Edgar Link	pending
tpg6.jpg	Edgar Link	pending
tpg95.jpg	Edgar Link	pending
v369260_10k.htm	Edgar Link	pending
v369260_ex23-1.htm	Edgar Link	pending
v369260_ex31-1.htm	Edgar Link	pending
v369260_ex31-2.htm	Edgar Link	pending
v369260_ex32-1.htm	Edgar Link	pending
v369260_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PLX
Protalix BioTherapeutics, Inc. Stock $plx

2014 Q1 Form 10-K Financial Statement

#000114420414015468 Filed on March 13, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLX Protalix BioTherapeutics, Inc. Stock $plx

2014 Q1 Form 10-K Financial Statement

#000114420414015468 Filed on March 13, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLX
Protalix BioTherapeutics, Inc. Stock $plx